Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, November 17, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Salveen Richter Upgraded (AGIO) to Hold and Increased Target to $32 on, Nov 17th, 2022
Salveen Richter of Goldman Sachs, Upgraded "Agios Pharmaceuticals, Inc." (AGIO) to Hold and Increased Target from $17 to $32 on, Nov 17th, 2022.
Salveen has made no other calls on AGIO in the last 4 months.
There is 1 other peer that has a rating on AGIO. Out of the 1 peers that are also analyzing AGIO, 0 agree with Salveen's Rating of Hold.
This is the rating of the analyst that currently disagrees with Salveen
- Andrew Berens of "SVB Leerink" Maintained at Buy with Increased Target to $37 on, Friday, August 5th, 2022
